Article

Reducing Costs And Improving Adherence For Self-Administration Of New Biologics

Reducing Costs And Improving Adherence For Self-Administration Of New Biologics

Many of the newer biologic products being developed are for long-term administration in chronic disease conditions, including oncology, autoimmune disorders and high cholesterol. Historically, these biologics have been administered by costly intravenous (IV) injection in a hospital, clinic or doctor’s office. IV administration has been used due to the higher dosing requirements – upwards of 100 mg. To help improve patient compliance and lower the cost of therapy, some of these products have been reformulated down to 1 mL or below. At this volume they can be self-administered using an auto-injector for the 1 mL long pre-filled syringe.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Med Device Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

West Pharmaceutical Services, Inc.